Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pickering emulsion as an oral delivery platform of anti-TNF-α antibody for ulcerative colitis therapy.

International journal of pharmaceutics·2026
Same author

Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory Therapy.

ACS pharmacology & translational science·2026
Same author

Site- and Size-Controlled PEGylation Modulates Biointerfaces and Immunoregulatory Functions of Bifunctional Peptides in an Autoimmune Disease Model.

ACS applied materials & interfaces·2026
Same author

Route of Administration Determines the Immunosuppressive Mechanism of Bifunctional Peptide Inhibitors in a Mouse EAE Model.

Molecular pharmaceutics·2025
Same author

Tanshinone IIA-loaded nanoparticles and neural stem cell combination therapy improves gut homeostasis and recovery in a pig ischemic stroke model.

Scientific reports·2023
Same author

Identification of a Novel Keto Sugar Component in Streptococcus pneumoniae Serotype 12F Capsular Polysaccharide and Impact on Vaccine Immunogenicity.

Journal of immunology (Baltimore, Md. : 1950)·2023

Related Experiment Video

Updated: Jan 13, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.2K

Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.

Xiaodi Li1, Jin Xie1, Su Jeong Song1

  • 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.

ACS Biomaterials Science & Engineering
|January 7, 2026
PubMed
Summary

This study introduces targeted nanoparticles for bladder cancer therapy, combining chemotherapy and immunotherapy. The novel system enhances drug delivery, reduces tumor volume, and boosts anti-tumor immune responses for improved treatment outcomes.

Keywords:
bladder cancerchemo-immunotherapyliposome nanoparticlessialic acid targetingtargeted drug delivery

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.4K
Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
05:55

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

9.2K

Related Experiment Videos

Last Updated: Jan 13, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.2K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.4K
Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
05:55

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

9.2K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Targeted drug delivery is essential for effective bladder cancer treatment with reduced side effects.
  • Overexpression of sialic acid on bladder cancer cells presents a target for selective nanocarrier binding.

Purpose of the Study:

  • To develop a novel targeted nanocarrier system for enhanced bladder cancer therapy.
  • To evaluate a combination therapy of chemotherapy and immunotherapy using targeted nanoparticles.

Main Methods:

  • Liposomes were modified with 4-carboxyphenylboronic acid (CPBA) to target sialic acid residues.
  • Liposome-chitosan-CPBA nanoparticles (LPCB) were co-loaded with doxorubicin (Dox) and resiquimod (R848).
  • In vitro and in vivo studies assessed nanoparticle binding, cytotoxicity, biodistribution, tumor reduction, and immune cell activation.

Main Results:

  • LPCB nanoparticles demonstrated enhanced binding and cytotoxicity to bladder tumor cells.
  • Targeted nanoparticles showed preferential tumor accumulation in vivo.
  • Combination therapy significantly reduced tumor volume and activated key immune cells (NK, CD4+, CD8+ T cells).

Conclusions:

  • Sialic acid-targeted LPCB nanoparticles co-loaded with Dox and R848 (LPCBDR) represent a promising platform for bladder cancer treatment.
  • This targeted approach enhances therapeutic efficacy by combining direct tumor cell elimination with immune system activation.